These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Class B type I scavenger receptor is responsible for the high affinity cholesterol binding activity of intestinal brush border membrane vesicles. Labonté ED; Howles PN; Granholm NA; Rojas JC; Davies JP; Ioannou YA; Hui DY Biochim Biophys Acta; 2007 Sep; 1771(9):1132-9. PubMed ID: 17442616 [TBL] [Abstract][Full Text] [Related]
23. Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors. Burnett DA; Caplen MA; Browne ME; Zhau H; Altmann SW; Davis HR; Clader JW Bioorg Med Chem Lett; 2002 Feb; 12(3):315-8. PubMed ID: 11814786 [TBL] [Abstract][Full Text] [Related]
28. Simvastatin with or without ezetimibe in familial hypercholesterolemia. Davis HR; Murgolo NJ; Graziano MP N Engl J Med; 2008 Jul; 359(5):531; author reply 532-3. PubMed ID: 18677799 [No Abstract] [Full Text] [Related]
29. The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balance. Catapano AL Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():21-6. PubMed ID: 18001316 [TBL] [Abstract][Full Text] [Related]
30. Multiple plasma membrane receptors but not NPC1L1 mediate high-affinity, ezetimibe-sensitive cholesterol uptake into the intestinal brush border membrane. Knöpfel M; Davies JP; Duong PT; Kvaernø L; Carreira EM; Phillips MC; Ioannou YA; Hauser H Biochim Biophys Acta; 2007 Sep; 1771(9):1140-7. PubMed ID: 17689140 [TBL] [Abstract][Full Text] [Related]
31. The pharmacokinetics of ezetimibe. Simard C; Turgeon J Can J Clin Pharmacol; 2003; 10 Suppl A():13A-20A. PubMed ID: 14571304 [TBL] [Abstract][Full Text] [Related]
32. Cholesterol-lowering effect of ezetimibe in uridine diphosphate glucuronosyltransferase 1A-deficient (Gunn) rats. Yamamoto T; Ito K; Honma M; Takada T; Suzuki H Drug Metab Dispos; 2007 Sep; 35(9):1455-8. PubMed ID: 17567728 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393 [TBL] [Abstract][Full Text] [Related]
34. Drug treats two sources of cholesterol. Nurse Pract; 2005 Mar; 30(3):70. PubMed ID: 15753829 [No Abstract] [Full Text] [Related]
35. Ezetimibe and other azetidinone cholesterol absorption inhibitors. Clader JW Curr Top Med Chem; 2005; 5(3):243-56. PubMed ID: 15857308 [TBL] [Abstract][Full Text] [Related]
36. In vivo responsiveness to ezetimibe correlates with niemann-pick C1 like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1 orthologs. Hawes BE; O'neill KA; Yao X; Crona JH; Davis HR; Graziano MP; Altmann SW Mol Pharmacol; 2007 Jan; 71(1):19-29. PubMed ID: 17005902 [TBL] [Abstract][Full Text] [Related]
37. Intestinal cholesterol absorption: identification of different binding proteins for cholesterol and cholesterol absorption inhibitors in the enterocyte brush border membrane. Kramer W; Girbig F; Corsiero D; Burger K; Fahrenholz F; Jung C; Müller G Biochim Biophys Acta; 2003 Jul; 1633(1):13-26. PubMed ID: 12842191 [TBL] [Abstract][Full Text] [Related]
38. 2-Azetidinone cholesterol absorption inhibitors: structure-activity relationships on the heterocyclic nucleus. Clader JW; Burnett DA; Caplen MA; Domalski MS; Dugar S; Vaccaro W; Sher R; Browne ME; Zhao H; Burrier RE; Salisbury B; Davis HR J Med Chem; 1996 Sep; 39(19):3684-93. PubMed ID: 8809157 [TBL] [Abstract][Full Text] [Related]
39. Multiple strategies for the preparation of a sulfur-35 labeled NPC1L1 radioligand. Simeone JP; Braun MP; Leone JF; Lin P; DeVita RJ; Garcia-Calvo M; Bull HG; Lisnock J; Dean DC Bioorg Med Chem Lett; 2009 Sep; 19(17):5033-6. PubMed ID: 19631535 [TBL] [Abstract][Full Text] [Related]
40. Ezetimibe, an inhibitor of intestinal cholesterol absorption, decreases serum level of malondialdehyde-modified low-density lipoprotein in patients with hypercholesterolemia. Ueda S; Miyake I; Takata K; Shimizu N; Shirotani K; Ishida S; Yonemitsu K; Maeyama T; Saito F; Saito H; Yamagishi S Int J Cardiol; 2011 Feb; 146(3):420-1. PubMed ID: 21106263 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]